REG - Coiled Therapeutics - Commencement of Trading on US OTCQB Venture Market

Coiled TherapeuticsAnnouncement

19/05/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260519:nRSS7997Ea&default-theme=true

RNS Number : 7997E  Coiled Therapeutics PLC  19 May 2026

19 May 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

 

Commencement of Trading on US OTCQB Venture Market

 

Coiled Therapeutics (AIM:COIL), the clinical-stage oncology company developing
precision medicines for hard-to-treat cancers, announces that trading in the
Company's ordinary shares of one pence each ("Ordinary Shares") will commence
today on the OTCQB Venture Market in the United States. The Company's OTCQB
shares have the ticker: COTXF

 

Coiled Therapeutics' Ordinary Shares will continue to trade on the AIM Market
of the London Stock Exchange, under the ticker COIL.

 

Cross trading on the OTCQB market allows the Company to access one of the
world's largest investment markets to expand its reach into a broader pool of
investors. Coiled Therapeutics shares will be available to US investors during
US working hours and priced in US dollars and thus has the potential to enable
greater liquidity in the Company's shares on the London Stock Exchange by
easing cross-border trading for potential US investors. Further information
about the OTCQB market can be found at: www.otcmarkets.com/learn/market-101
(http://www.otcmarkets.com/learn/market-101)

 

As a Foreign Private Issuer, Coiled Therapeutics' onboarding to the OTC
Markets is based on satisfaction of the requirements for OTCQB as applicable
to international reporting companies including satisfaction of the criteria
for the exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting.
The Rule 12g3-2(b) exemption includes the disclosure obligation to ensure that
certain information made public or distributed under home market regulations
is made publicly available on the Company's website or other electronic
information delivery system in English. Thus, the Company will have no
additional reporting obligations and incur minimal ongoing costs, compared to
traditional major exchanges.

 

As a verified market, the OTCQB offers transparent trading for companies that
have met a minimum bid price test, are current in their financial reporting
and have undergone an annual verification and management certification
process. The cross-trading facility is provided through OTC Markets Group
Inc., located in New York. OTC Markets operates the world's largest electronic
interdealer quotation system for US broker dealers and offers multiple media
channels to increase the visibility of OTC-listed companies. Online brokers
such as Fidelity, TradeStation, Charles Schwab, Interactive Brokers and
E-trade all offer trading of OTCQB shares. US investors can find real-time
quotes, market information and access current company news and developments
for Coiled Therapeutics at https://www.otcmarkets.com/stock/COTXF/overview
(https://www.otcmarkets.com/stock/COTXF/overview) .

 

Sridhar Vempati, Chief Executive Officer of Coiled Therapeutics, commented:

"We are pleased to commence trading on the OTCQB Venture Market, which we
believe complements our AIM listing well by opening up Coiled Therapeutics to
a broader pool of US-based investors and the potential for enhanced liquidity
in our shares. This is an exciting time for the Company, following the highly
encouraging clinical data from Cohort 4b in our ongoing clinical trial, which
delivered an 80% Clinical Benefit Rate and durable responses in a heavily
pre-treated patient population. With dose escalation on track for completion
in H1 2026 and multiple data catalysts ahead, we believe 2026 will be a
transformational year for Coiled Therapeutics, and we look forward to
welcoming new US investors as we deliver on our clinical and strategic
milestones."

 

Enquiries:

 Coiled Therapeutics plc

 Sotirios Stergiopoulos (Chairman)                                          Via Burson Buchanan

 Sridhar Vempati (CEO)

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)  +44 (0)20 3470 0470

 David Hignell / Adam Cowl / Devik Mehta (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Shard Capital Partners LLP (Joint Broker)                            +44 (0)20 4530 6926

 Damon Heath

 CPS Capital Group Pty Ltd (Joint Broker)                             +61 (0)8 9223 2222

 Jason Peterson / David Valentino

 Burson Buchanan (Public Relations)                                   +44 (0)20 7466 5000

 Henry Harrison Topham / Jamie Hooper / Toto Berger

 Harbor Access (US Investor Relations)                                +1 475 477 9404

 Matt Kelly / Jonathan Paterson

 

 

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology
company focused on developing innovative precision oncology therapies. Its
lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I
clinical trials in the USA (trials ID: NCT06136884).  Coiled Therapeutics is
actively enrolling patients to test for safety and efficacy in patients whose
cancer has progressed on other treatments.   The Company is also assessing
its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is
supported by a leadership team with a proven track record in drug development
and strategic backing from A2A Pharmaceuticals.

 

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small
molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3
(TACC3). TACC3 is a validated oncology target that is frequently overexpressed
in many aggressive, hard-to-treat solid tumours but is dispensable in normal
adult cells, providing a wide therapeutic window.

 

By selectively disrupting cancer-critical protein-protein interactions at the
TACC3 C-terminal domain, AO-252 induces mitotic and replication stress,
impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has
demonstrated the ability to cross the blood-brain barrier, addressing a
significant unmet medical need for the treatment of brain metastases.

 

The asset is currently in an ongoing Phase I open-label dose-escalation study
and early clinical signals have shown encouraging anti-tumour activity and a
benign safety profile, with the Company planning to initiate dose expansion
cohorts in lead indications, including prostate and ovarian cancer, during
2026.

 

For more information, please visit: www.coiledplc.com
(http://www.coiledplc.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAXSPFFNKEFA



            Copyright 2019 Regulatory News Service, all rights reserved